Ocugen Inc OCGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa
-
Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference
-
Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm
-
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
-
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
-
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
-
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
-
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
Trading Information
- Previous Close Price
- $0.95
- Day Range
- $0.96–1.03
- 52-Week Range
- $0.35–2.11
- Bid/Ask
- $1.00 / $1.01
- Market Cap
- $290.74 Mil
- Volume/Avg
- 3.2 Mil / 4.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 31.69
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 84
- Website
- https://www.ocugen.com
Comparables
Valuation
|
Metric
|
OCGN
|
TSHA
|
DSGN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 51.55 | — |
Price/Book Value | 15.36 | 3.72 | 1.08 |
Price/Sales | 31.69 | 31.27 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
OCGN
TSHA
DSGN
Financial Strength
|
Metric
|
OCGN
|
TSHA
|
DSGN
|
|---|---|---|---|
Quick Ratio | 0.87 | 5.05 | 41.04 |
Current Ratio | 1.04 | 5.22 | 41.42 |
Interest Coverage | — | −52.79 | — |
Quick Ratio
OCGN
TSHA
DSGN
Profitability
|
Metric
|
OCGN
|
TSHA
|
DSGN
|
|---|---|---|---|
Return on Assets (Normalized) | −67.55% | −40.83% | −13.14% |
Return on Equity (Normalized) | −100.04% | −216.63% | −13.70% |
Return on Invested Capital (Normalized) | −86.57% | −77.31% | −13.56% |
Return on Assets
OCGN
TSHA
DSGN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Kmbvcjqkz | Bjn | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Pyxrcpt | Sxcfsb | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Blkkphvh | Yqwhy | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Cbljgbzf | Xjwwyr | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Psgxgfql | Lcbjf | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Fmhzfhqkg | Xkmv | $29.2 Bil | |||
| Moderna Inc
MRNA
| Zsjpqxmw | Zyys | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Rbynfjgx | Blf | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Cwdysdfl | Jjnqfs | $13.2 Bil | |||
| Incyte Corp
INCY
| Vbpjfnvk | Lgtps | $13.0 Bil |
United States